Authors:
KELLOFF GJ
CROWELL JA
HAWK ET
STEELE VE
LUBET RA
BOONE CW
COVEY JM
DOODY LA
OMENN GS
GREENWALD P
HONG WK
PARKINSON DR
BAGHERI D
BAXTER GT
BLUNDEN M
DOELTZ MK
EISENHAUER KM
JOHNSON K
KNAPP GG
LONGFELLOW DG
MALONE WF
NAYFIELD SG
SEIFRIED HE
SWALL LM
SIGMAN CC
Citation: Gj. Kelloff et al., STRATEGY AND PLANNING FOR CHEMOPREVENTIVE DRUG DEVELOPMENT - CLINICALDEVELOPMENT PLANS-II, Journal of cellular biochemistry, 1996, pp. 54-71
Authors:
KELLOFF GJ
CROWELL JA
HAWK ET
STEELE VE
LUBET RA
BOONE CW
COVEY JM
DOODY LA
OMENN GS
GREENWALD P
HONG WK
PARKINSON DR
BAGHERI D
BAXTER GT
BLUNDEN M
DOELTZ MK
EISENHAUER KM
JOHNSON K
KNAPP GG
LONGFELLOW DG
MALONE WF
NAYFIELD SG
SEIFRIED HE
SWALL LM
SIGMAN CC
Citation: Gj. Kelloff et al., CLINICAL DEVELOPMENT PLANS FOR CANCER CHEMOPREVENTIVE AGENTS, Journal of cellular biochemistry, 1996, pp. 72-321
Authors:
DECENSI A
BRUNO S
COSTANTINI M
TORRISI R
CUROTTO A
GATTESCHI B
NICOLO G
POLIZZI A
PERLOFF M
MALONE WF
BRUZZI P
Citation: A. Decensi et al., PHASE-IIA STUDY OF FENRETINIDE IN SUPERFICIAL BLADDER-CANCER, USING DNA FLOW-CYTOMETRY AS AN INTERMEDIATE END-POINT, Journal of the National Cancer Institute, 86(2), 1994, pp. 138-140
Authors:
CROWELL JA
GOLDENTHAL EI
KELLOFF GJ
MALONE WF
BOONE CW
Citation: Ja. Crowell et al., CHRONIC TOXICITY STUDIES OF THE POTENTIAL CANCER PREVENTIVE 2-(DIFLUOROMETHYL)-DL-ORNITHINE, Fundamental and applied toxicology, 22(3), 1994, pp. 341-354